Inventiva stock analysis
Inventiva (6IVA) Stock Price & Analysis
6IVA Stock Chart & Stats
- Day’s Range
- EUR 3.26 - EUR 3.46
- 52-Week Range
- EUR 2.32 - EUR 6.20
- Previous Close
- EUR 3.52
- Volume
- N/A
- Average Volume (3M)
- 128
- Market Cap
- EUR 810.56M
- Enterprise Value
- EUR 920.42M
- Total Cash (Recent Filing)
- EUR 166.06M
- Total Debt (Recent Filing)
- EUR 66.63M
- Price to Earnings (P/E)
- ―
- Beta
- 1.03
- Next Earnings
- Mar 31, 2027 (Est.)
- EPS Estimate
- -0.29
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Large Late-stage Clinical Program
A large, fully recruited Phase III program provides a substantial clinical test of lanifibranor across relevant MASH stages. The trial’s scale and advanced development status support a potentially meaningful value inflection if efficacy and safety results validate the program.
Promising Phase II Efficacy
The Phase II-B histological results provide clinical support for lanifibranor’s mechanism and help differentiate the lead asset in a disease with substantial unmet need. Reproducibility in Phase III could underpin regulatory progress and future commercial adoption.
Financing Supports Key Milestones
Runway extending through the anticipated Phase III readout and potential NDA filing reduces immediate funding pressure during the most important development period. This gives management greater ability to execute milestones before needing additional capital, subject to financing assumptions.
Bears Say
Deep And Persistent Operating Losses
Severe losses relative to revenue show that Inventiva has not yet achieved operating leverage and remains dependent on external financing. Continued development spending without commercial product sales could keep profitability distant and increase dilution or funding pressure.
Persistent Cash Burn And Weak Cash Generation
Ongoing negative operating and free cash flow means the business consumes cash to fund research and clinical development rather than generating internal resources. Higher recent burn can shorten financial flexibility and make future milestones more dependent on financing access.
Safety And Approval Uncertainty
Tolerability effects could affect treatment persistence, physician acceptance, or the eventual benefit-risk assessment for lanifibranor. Because regulatory filings and any commercial launch remain conditional on Phase III and approval outcomes, the lead program still carries material execution risk.
Inventiva News
6IVA FAQ
What was Inventiva’s price range in the past 12 months?
What is Inventiva’s market cap?
When is Inventiva’s upcoming earnings report date?
How were Inventiva’s earnings last quarter?
Is Inventiva overvalued?
Does Inventiva pay dividends?
What is Inventiva’s EPS estimate?
How many shares outstanding does Inventiva have?
What happened to Inventiva’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Inventiva?
What is the TipRanks Smart Score and how is it calculated?
Inventiva Stock Smart Score
Company Description
Inventiva
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Andrew Obenshain
- Employees
- 77
- Website
- www.inventivapharma.com
- Address
- 50 rue de Dijon, Daix, BF, 21121, FR
Inventiva (6IVA) Earnings & Revenues
6IVA Company Deck
6IVA Earnings Call
Earnings Call SentimentPositive
The call was strongly focused on progress toward the NATiV3 phase III readout, positive phase II-B efficacy, preparation for potential regulatory and commercial milestones, and a strengthened financial position. Management also addressed known tolerability considerations, including weight gain, edema, and hemoglobin decline, while withholding additional blinded phase III safety and efficacy details. The positive development, financing, and preparation updates significantly outweighed the disclosed challenges and uncertainties.
View all DE:6IVA earnings summaries6IVA Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 6 | 3 |
| Technical Analysis | 3 | 6 | 1 |
| Moving Averages | 10 | 0 | 2 |











